Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an agile team with a championship mindset.

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol ...

A client in Ireland acquired an aseptic operations facility with plans to expand into GMP microbiology laboratory services, despite having previously outsourced all microbiology work and lacking ...

<p data-pm-slice="1 1 []">Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity ...

<p>Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

Sustainability used to be just about saving the planet. Today it has morphed into an umbrella term for environmental, social, and governance (ESG) issues. Mentions of ESG and related topics in pharma ...

<p>Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.</p> ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

EY's Arda Ural evaluates the life sciences business environment and shares reasons for optimism about growth despite policy changes in 2025.